The FDA has granted accelerated approval to Karyopharm Therapeutics’ Xpovio (selinexor) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma.

The approval was based on the results of a phase 2 clinical trial in which Xpovio demonstrated an overall response rate of 29 percent.

Xpovio had been granted priority review and fast-track designations.